Acorda Therapeutics Inc (ACOR) Position Lowered by First Quadrant L P CA

Share on StockTwits

First Quadrant L P CA decreased its stake in Acorda Therapeutics Inc (NASDAQ:ACOR) by 47.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,778 shares of the biopharmaceutical company’s stock after selling 13,219 shares during the period. First Quadrant L P CA’s holdings in Acorda Therapeutics were worth $290,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Northern Trust Corp lifted its stake in shares of Acorda Therapeutics by 0.7% in the second quarter. Northern Trust Corp now owns 1,049,729 shares of the biopharmaceutical company’s stock valued at $30,127,000 after purchasing an additional 7,606 shares during the period. Millennium Management LLC raised its position in Acorda Therapeutics by 269.6% during the first quarter. Millennium Management LLC now owns 734,774 shares of the biopharmaceutical company’s stock worth $17,377,000 after acquiring an additional 535,970 shares during the last quarter. Renaissance Technologies LLC raised its position in Acorda Therapeutics by 228.1% during the second quarter. Renaissance Technologies LLC now owns 680,900 shares of the biopharmaceutical company’s stock worth $19,542,000 after acquiring an additional 473,400 shares during the last quarter. Principal Financial Group Inc. raised its position in Acorda Therapeutics by 2.9% during the first quarter. Principal Financial Group Inc. now owns 367,973 shares of the biopharmaceutical company’s stock worth $8,703,000 after acquiring an additional 10,536 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Acorda Therapeutics by 13.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 330,943 shares of the biopharmaceutical company’s stock worth $9,499,000 after acquiring an additional 38,414 shares during the last quarter.

A number of equities analysts have issued reports on ACOR shares. HC Wainwright set a $31.00 target price on shares of Acorda Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 26th. ValuEngine cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Tuesday, July 3rd. Cowen restated a “buy” rating and set a $30.00 target price on shares of Acorda Therapeutics in a research report on Thursday, August 2nd. Finally, BidaskClub upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $24.17.

In other news, major shareholder Scopia Capital Management Lp sold 13,829 shares of Acorda Therapeutics stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $27.82, for a total transaction of $384,722.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 490,832 shares of company stock valued at $9,121,364. Insiders own 7.80% of the company’s stock.

Shares of ACOR opened at $17.48 on Wednesday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.56. The stock has a market cap of $886.52 million, a price-to-earnings ratio of 16.81 and a beta of 1.51. Acorda Therapeutics Inc has a 12-month low of $15.60 and a 12-month high of $36.35.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.90. The business had revenue of $153.30 million during the quarter, compared to the consensus estimate of $138.63 million. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.29 earnings per share. As a group, research analysts anticipate that Acorda Therapeutics Inc will post -0.03 earnings per share for the current year.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Article: What are retained earnings?

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply